Probe-induced heteroduplex mobility assay
The probe-induced heteroduplex mobility assay (PRIMA) addresses the limitations of existing methods by enhancing the detection of 1 bp differences in nucleic acid sequences, offering cost-effective and time-efficient genotyping and SNP typing solutions.
Patent Information
- Application Number
- JP2022507594
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-08
- Filing Date
- 2020-08-10
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-08-10
AI Technical Summary
Existing methods for detecting single base pair differences, such as Sanger sequencing and HMA, are costly, time-consuming, or lack the resolution to distinguish between 1 bp insertion or deletion mutations, which are crucial for identifying frameshift null mutations in genome editing studies.
A novel probe-induced heteroduplex mobility assay (PRIMA) using synthetic oligo DNA sequences with artificially introduced insertions or deletions, combined with PCR and electrophoresis, to enhance the resolution of heteroduplex peak detection.
PRIMA effectively distinguishes 1 bp differences in nucleic acid sequences, reducing costs and time by providing clear heteroduplex peaks, enabling efficient genotyping and SNP typing across various species.
Smart Images

Figure 0007589951000010 
Figure 0007589951000011 
Figure 0007589951000012
Abstract
Description
[Technical field]
[0001] background In recent years, with the development of double strand break (DSB)-based gene editing technologies (ZFN / TALEN / CRIPSR, etc.), there is an increasing demand for detecting single base pair (bp) differences in molecular biology. These DSBs can stimulate non-homologous end joining (NHEJ) in the target genomic sequence, resulting in 1-bp insertion or deletion indel mutations. Researchers are often interested in these 1-bp indel mutations that result in frameshift null mutations. To identify such mutations from a screening population, a large number of genotyping experiments are first required, and once the mutations are identified, large-scale homozygous and heterozygous genotyping may be required for subsequent analysis. Such experiments are common in many organisms (human; Mali et al., 2013 Science / mouse; Wang et al., Cell 2013 / monkey; Wan et al., 2015 Cell Res 2014 / C. elegans; Friedland Nat Methods 2013 / Dorosophila; Venken et al., Dev Biol., 2016 Zebrafish; Hwang et al., 2013 Nat biotech / Athal N. benthamiana; Li et al., Nat biotech 2013 / sorghum rice; Jiang et al., NAR 2013 / wheat; Upadhyay et al., G3 2013).Many studies have developed methods to detect differences of a few base pairs, such as Sanger sequencing or deep sequencing, restriction fragment length polymorphism (RFLP) analysis (Urnov et al., 2005 Nature), DNA melting analysis (Dahlem et al., 2012 PLoS Genet), T7 endonuclease I assay (Kim et al., 2009 Genome Res), Cel-1 assay (Ueta et al., 2017 Scientific Rep), fluorescent polymerase chain reaction (PCR) (Kim et al., 2011 Nat methods), and analysis based on RNA-guided endonuclease and restriction fragment length polymorphism (RGEN-RFLP) (Kim et al., 2014 Nat Comn). However, each method has its own advantages and disadvantages. For example, Sanger sequencing and deep sequencing can identify DNA sequences with a resolution of 1 bp, but they are costly and time-consuming. RFLP analysis can achieve 1 bp resolution when the sequence information to be distinguished is already known and an assay can be designed using existing restriction enzymes. Under these conditions, RFLP is not suitable for screening mutants. DNA melting analysis, T7 endonuclease I assay, Cel-1 assay, fluorescent PCR, and RGEN-RFLP do not always achieve 1 bp resolution and / or require special chemicals, proteins, and devices. Summary of the Invention [Problem to be solved by the invention]
[0002] Heteroduplex mobility assay (HMA) is also a method to detect small base pair differences (Kumeda and Asao 2001, Appl Environ Microbiol; Ota et al. 2013 Genes Cells; Ansai et al. 2014 Dev Growth Differ; Bhattacharyya and Lilley 1989 NAR). HMA consists of three simple steps: 1) PCR, 2) denaturation / reannealing, and 3) electrophoresis (Figure 1). However, since the resolution of HMA is usually 3 base pairs or more (Ota et al. 2013 Genes Cells; Ansai et al. 2014 Dev Growth Differ; Bhattacharyya and Lilley 1989 NAR), it is usually difficult to distinguish 1 bp differences using HMA (Sugano et al. 2017). [Means for solving the problem]
[0003] The present invention provides a novel method for detecting a sequence with a difference of 1 bp using synthetic oligo DNA sequences with artificially inserted or deleted sequences and PCR-amplified double-stranded DNA or short single-stranded DNA as a probe. The present inventors herein call this method probe-induced HMA ( Pr obe- I Induced H MA The system is called PRIMA. PRIMA can be widely applied to genome editing in a variety of biological species.
[0004] The arrangements in the figures are referred to separately following the description of the figures. [Brief description of the drawings]
[0005] [Figure 1a]Figure 1 shows an overview of HMA (a), prePRIMA (b), and PRIMA (c). HMA has difficulty generating detectable peaks with heteroduplex mobility shifts due to 1 bp difference (a). On the other hand, prePRIMA (b) and PRIMA (c) can generate heteroduplex peaks from wild type (WT) and 1 bp indel sequences. WT; wild type, mt; mutant, Homo; homozygote, Hetero; heterozygote, sss; short single strand. Represents the 1 bp insertion / deletion mutation point. Open and filled triangles indicate heteroduplex peaks from wild type and mutant, respectively. Circles on the electropherogram indicate the mixture of homoduplex peaks and indistinguishable heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 1b] Figure 1 shows an overview of HMA (a), prePRIMA (b), and PRIMA (Cc). HMA has difficulty generating detectable peaks with a shift in heteroduplex mobility due to a 1-bp difference (a). On the other hand, prePRIMA (b) and PRIMA (c) can generate heteroduplex peaks from wild type (WT) and 1-bp indel sequences. WT; wild type, mt; mutant, Homo; homozygote, Hetero; heterozygote, sss; short single strand. Represents the 1-bp insertion / deletion mutation point. Open and filled triangles indicate heteroduplex peaks from wild type and mutant, respectively. Circles on the electropherogram indicate a mixture of homoduplex peaks and indistinguishable heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 1c]Figure 1 shows an overview of HMA (a), prePRIMA (b), and PRIMA (c). HMA has difficulty generating detectable peaks with heteroduplex mobility shifts due to 1 bp difference (a). On the other hand, prePRIMA (b) and PRIMA (c) can generate heteroduplex peaks from wild type (WT) and 1 bp indel sequences. WT; wild type, mt; mutant, Homo; homozygote, Hetero; heterozygote, sss; short single strand. Represents the 1 bp insertion / deletion mutation point. Open and filled triangles indicate heteroduplex peaks from wild type and mutant, respectively. Circles on the electropherogram indicate the mixture of homoduplex peaks and indistinguishable heteroduplex peaks. Stars indicate homoduplex peaks. [Diagram 2] Figure 2 shows an example of sequence and probe design. Alignment of the first sequence (S1), the second sequence (S2) and the probe (P). The first variable sequence tract V1 has a length of 5 nucleotides and the second variable sequence tract has a length of 4 nucleotides. X: no nucleotides (missing for V1), C1: first 5' consensus sequence tract, C1': second 5' consensus sequence tract (same as C1), C2: first 3' consensus sequence tract, C2': second 3' consensus sequence tract (same as C2), RC1: reverse complementary sequence to C1, RC2: reverse complementary sequence to C2, black lines: first and second sequences. [Diagram 3] Figure 3 shows an example of sequence and probe design. Alignment of the first sequence (S1), the second sequence (S2) and the probe (P). The first variable sequence tract V1 has a length of 5 nucleotides. X and Y: no nucleotides (missing for V1), C1: first 5' consensus sequence tract, C1': second 5' consensus sequence tract (3 nucleotides shorter than C1), C2: first 3' consensus sequence tract, C2': second consensus sequence tract (identical to C2), RC1: reverse complementary sequence to C1, RC2: reverse complementary sequence to C2, black lines: first and second sequences. [Figure 4a]Figure 4 shows heteroduplex peaks of wild-type and 1-bp insertion / deletion mutants of plant (a, b, c), bacterial (d), and human (c) DNA fragments detected by prePRIMA. Arrows indicate the heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 4b] Figure 4 shows heteroduplex peaks of wild-type and 1-bp insertion / deletion mutants of plant (a, b, c), bacterial (d), and human (c) DNA fragments detected by prePRIMA. Arrows indicate the heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 4c] Figure 4 shows heteroduplex peaks of wild-type and 1-bp insertion / deletion mutants of plant (a, b, c), bacterial (d), and human (c) DNA fragments detected by prePRIMA. Arrows indicate the heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 4d] Figure 4 shows heteroduplex peaks of wild-type and 1-bp insertion / deletion mutants of plant (a, b, c), bacterial (d), and human (c) DNA fragments detected by prePRIMA. Arrows indicate the heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 4e] Figure 4 shows heteroduplex peaks of wild-type and 1-bp insertion / deletion mutants of plant (a, b, c), bacterial (d), and human (c) DNA fragments detected by prePRIMA. Arrows indicate the heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 5a] FIG. 5 shows the detection of 0-7 bp gap sequences in RDP1 by HMA using 130 bp (b) and 300 bp (c) PCR fragments. [Figure 5b] FIG. 5 shows the detection of 0-7 bp gap sequences in RDP1 by HMA using 130 bp (b) and 300 bp (c) PCR fragments. [Figure 5c] FIG. 5 shows the detection of 0-7 bp gap sequences in RDP1 by HMA using 130 bp (b) and 300 bp (c) PCR fragments. [Figure 6a] FIG. 6 shows the detection of 0-7 bp gap sequences in DML1 by HMA using 153 bp (b) and 300 bp (c) PCR fragments. [Figure 6b]FIG. 6 shows the detection of 0-7 bp gap sequences in DML1 by HMA using 153 bp (b) and 300 bp (c) PCR fragments. [Figure 6c] FIG. 6 shows the detection of 0-7 bp gap sequences in DML1 by HMA using 153 bp (b) and 300 bp (c) PCR fragments. [Figure 7a-1] Figure 7 shows detection of 0-7 bp gap sequences by HMA. (a) RDP1, (b) DML1. Arrows indicate heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 7a-2] Figure 7 shows detection of 0-7 bp gap sequences by HMA. (a) RDP1, (b) DML1. Arrows indicate heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 7b-1] Figure 7 shows detection of 0-7 bp gap sequences by HMA. (a) RDP1, (b) DML1. Arrows indicate heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 7b-2] Figure 7 shows detection of 0-7 bp gap sequences by HMA. (a) RDP1, (b) DML1. Arrows indicate heteroduplex peaks. Stars indicate homoduplex peaks. [Figure 8a] Figure 8 shows that when the mutation site is close to the end of the DNA fragment (a, b, c), the PRIMA probe does not function, and the probe length does not affect the heteroduplex peak (c) (a, b). No heteroduplex peak is formed when a primer pair (filled arrows) is used close to the mutation site (a, b). On the other hand, when the mutation site is near the center of the DNA fragment, a heteroduplex peak is generated (open arrows, a, c). No significant difference was detected between the 40-mer and 80-mer probes (c). The asterisk indicates the homoduplex peak. [Figure 8b]Figure 8 shows that when the mutation site is close to the end of the DNA fragment (a, b, c), the PRIMA probe does not function, and the probe length does not affect the heteroduplex peak (c) (a, b). No heteroduplex peak is formed when a primer pair (filled arrows) is used close to the mutation site (a, b). On the other hand, when the mutation site is near the center of the DNA fragment, a heteroduplex peak is generated (open arrows, a, c). No significant difference was detected between the 40-mer and 80-mer probes (c). The asterisk indicates the homoduplex peak. [Figure 8c] Figure 8 shows that when the mutation site is close to the end of the DNA fragment (a, b, c), the PRIMA probe does not function, and the probe length does not affect the heteroduplex peak (c). No heteroduplex peak is formed when a primer pair close to the mutation site (filled arrows) is used (a, b). On the other hand, when the mutation site is near the center of the DNA fragment, a heteroduplex peak is generated (open arrows, a, c). No significant difference was detected between the 40-mer and 80-mer probes (c). The asterisk indicates the homoduplex peak. [Figure 9a]FIG. 9 shows the electrophoretic patterns from the 10 bp deletion sequence to the 10 bp insertion sequence by PRIMA. a. Sequence of RDP1. The 225 bp sequence of RDP1 was used in this analysis. The open arrows indicate the primer region, and the closed arrows indicate the probe region. The sequences from the 10 bp deletion to the 10 bp insertion used are shown below. b and c are polyacrylamide gel images by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in b, and from the wild type to the 10 bp insertion (ins) are shown in c. d and e are images of MultiNa by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in d, and the electrophoretic patterns from the wild type to the 10 bp insertion (ins) are shown in e. [Figure 9bc] FIG. 9 shows the electrophoretic patterns from the 10 bp deletion sequence to the 10 bp insertion sequence by PRIMA. a. Sequence of RDP1. The 225 bp sequence of RDP1 was used in this analysis. The open arrows indicate the primer region, and the closed arrows indicate the probe region. The sequences from the 10 bp deletion to the 10 bp insertion used are shown below. b and c are polyacrylamide gel images by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in b, and from the wild type to the 10 bp insertion (ins) are shown in c. d and e are images of MultiNa by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in d, and the electrophoretic patterns from the wild type to the 10 bp insertion (ins) are shown in e. [Figure 9d]FIG. 9 shows the electrophoretic patterns from the 10 bp deletion sequence to the 10 bp insertion sequence by PRIMA. a. Sequence of RDP1. The 225 bp sequence of RDP1 was used in this analysis. The open arrows indicate the primer region, and the closed arrows indicate the probe region. The sequences from the 10 bp deletion to the 10 bp insertion used are shown below. b and c are polyacrylamide gel images by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in b, and from the wild type to the 10 bp insertion (ins) are shown in c. d and e are images of MultiNa by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in d, and the electrophoretic patterns from the wild type to the 10 bp insertion (ins) are shown in e. [Figure 9e] FIG. 9 shows the electrophoretic patterns from the 10 bp deletion sequence to the 10 bp insertion sequence by PRIMA. a. Sequence of RDP1. The 225 bp sequence of RDP1 was used in this analysis. The open arrows indicate the primer region, and the closed arrows indicate the probe region. The sequences from the 10 bp deletion to the 10 bp insertion used are shown below. b and c are polyacrylamide gel images by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in b, and from the wild type to the 10 bp insertion (ins) are shown in c. d and e are images of MultiNa by PRIMA. The asterisks indicate the homoduplex peaks. The open and closed arrows indicate the heteroduplexes from the wild-type and mutant sequences, respectively. The electrophoretic patterns from the 10 bp deletion (del) to the wild type are shown in d, and the electrophoretic patterns from the wild type to the 10 bp insertion (ins) are shown in e. [Figure 10ab]Figure 10 shows genotyping using HMA, prePRIMA and PRIMA. (a) Workflow of genotyping with HMA. HMA requires two runs. The first run is reannealed with the sample alone. If a heteroduplex peak is formed, the sample is heterozygous. If no heteroduplex peak is formed, the sample is either wild type or mutant homozygous. The second run is reannealed with the wild type sample. If a heteroduplex peak is formed, the sample is mutant homozygous, if not, wild type homozygous. (b) Workflow of genotyping with PRIMA and prePRIMA. Only one run is required to detect the genotype. [Figure 10c] Examples of genotyping are shown in (c) for prePRIMA and (d) for PRIMA, with asterisks indicating homoduplex peaks. [Figure 10d] Examples of genotyping are shown in (c) for prePRIMA and (d) for PRIMA, with asterisks indicating homoduplex peaks. [Figure 11] FIG. 11 shows genotyping by PRIMA using a 225 bp PCR product of the RDP1 gene and a 40-mer probe with a 5-nucleotide deletion. [Figure 12a] Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Figure 12b] Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Figure 12c]Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Figure 12d] Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Fig. 12ef] Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Figure 12gh] Figure 12 shows the detection of 1-bp differences in many sequences from plants (a, b, e, f), humans (c, g), and bacteria (d, h) using PRIMA. Electropherogram patterns were obtained using MultiNA (a-d), and gel images were obtained using polyacrylamide gel electrophoresis (e-h). [Figure 13a]Figure 13 shows that PRIMA can distinguish between base types (A, T, G, C). To verify whether PRIMA can be further used for SNP typing, PRIMA was performed on the base-edited sequence (a) using two types of probes (a, b, c). In b, the nucleotides A / G and T / C are distinguishable because they generate different heteroduplex peaks. In c, A / G, T, and C were distinguishable. These results suggest that PRIMA may expand the application of SNP typing. In a; the unfilled arrows indicate the primers, and the light gray and dark gray arrows indicate the probes used in b (light gray) and c (dark gray). The base editing points are indicated by black arrows. Figures b and c are SNP typing by PRIMA using the 5531 probe (b) and the 5428 probe (c). The black, light gray, dark gray, and gray arrows indicate the heteroduplex peaks from A, T, G, and C, respectively. [Figure 13b] Figure 13 shows that PRIMA can distinguish between base types (A, T, G, C). To verify whether PRIMA can be further used for SNP typing, PRIMA was performed on the base-edited sequence (a) using two types of probes (a, b, c). In b, the nucleotides A / G and T / C are distinguishable because they generate different heteroduplex peaks. In c, A / G, T, and C were distinguishable. These results suggest that PRIMA may expand the application of SNP typing. In a; the unfilled arrows indicate the primers, and the light gray and dark gray arrows indicate the probes used in b (light gray) and c (dark gray). The base editing points are indicated by black arrows. Figures b and c are SNP typing by PRIMA using the 5531 probe (b) and the 5428 probe (c). The black, light gray, dark gray, and gray arrows indicate the heteroduplex peaks from A, T, G, and C, respectively. [Figure 13c]Figure 13 shows that PRIMA can distinguish between base types (A, T, G, C). To verify whether PRIMA can be further used for SNP typing, PRIMA was performed on the base-edited sequence (a) using two types of probes (a, b, c). In b, the nucleotides A / G and T / C are distinguishable because they generate different heteroduplex peaks. In c, A / G, T, and C were distinguishable. These results suggest that PRIMA may expand the application of SNP typing. In a; the unfilled arrows indicate the primers, and the light gray and dark gray arrows indicate the probes used in b (light gray) and c (dark gray). The base editing points are indicated by black arrows. Figures b and c are SNP typing by PRIMA using the 5531 probe (b) and the 5428 probe (c). The black, light gray, dark gray, and gray arrows indicate the heteroduplex peaks from A, T, G, and C, respectively. [Figure 14a] Figure 14 shows a 1 bp difference in detection with PRIMA. a: Gene construction of RDP1. Open arrows indicate primer regions and filled arrows indicate probe regions. Boxes indicate the positions of mutations. b: Heteroduplex peak detection with MultiNA. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. c: Heteroduplex peak detection with polyacrylamide gel. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. Marker (M) sizes are indicated on the left. Heteroduplex peaks of different sizes were detected by MultiNA and PAGE from 1ins (1 insertion), wild type, and 1del (1 deletion) sequences. [Figure 14b]Figure 14 shows a 1 bp difference in detection with PRIMA. a: Gene construction of RDP1. Open arrows indicate primer regions and filled arrows indicate probe regions. Boxes indicate the positions of mutations. b: Heteroduplex peak detection with MultiNA. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. c: Heteroduplex peak detection with polyacrylamide gel. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. Marker (M) sizes are indicated on the left. Heteroduplex peaks of different sizes were detected by MultiNA and PAGE from 1ins (1 insertion), wild type, and 1del (1 deletion) sequences. [Figure 14c] Figure 14 shows a 1 bp difference in detection with PRIMA. a: Gene construction of RDP1. Open arrows indicate primer regions and filled arrows indicate probe regions. Boxes indicate the positions of mutations. b: Heteroduplex peak detection with MultiNA. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. c: Heteroduplex peak detection with polyacrylamide gel. Stars indicate homoduplex peaks and arrows indicate heteroduplex peaks. Marker (M) sizes are indicated on the left. Heteroduplex peaks of different sizes were detected by MultiNA and PAGE from 1ins (1 insertion), wild type, and 1del (1 deletion) sequences. [Figure 15] Figure 15 shows the PRIMA procedure. [Figure 16] FIG. 16 shows an alternative approach for describing the variable sequence tract V. [Figure 17a]FIG. 17 shows a comparison of deletion or insertion probes with 1 bp indel mutants. The expected bulge structure shows that the deletion probe has a simpler and more distinguishable bulge than the insertion probe, even though the mutation position is shifted by several bp (FIG. 17). Therefore, rather than using a 5 bp insertion probe, it is preferable to use a 5 bp deletion probe so that the bulge size is different from the WT even if the 1 bp indel position is several bp away. This is because it is known that the exact indel position induced by a single CRISPR experiment can vary within a range of several bp (Nishida et al., Science 353, (2016)). The expected bulge structure in the wild type and the 1 bp indel mutant with a 5 bp position shift mutation (-2 to +3) is shown. The deletion probe generates a distinguishable and simple bulge structure from all the insertion type (a) and deletion type (b) mutants. On the other hand, for the insertion probe, only the "+1" and "+2" simple bulge structures are obtained in the deletion series (a), and only the "+1" simple bulge structure is obtained in the insertion series (b). The upper strand in the heteroduplex diagram is derived from the sample DNA. The lower strand in the heteroduplex diagram is derived from the probe DNA. The arrow indicates the +1 position. The grey line indicates the null nucleotide. The filled arrow indicates the 5 bp inserted nucleotide in the insertion probe. The unfilled arrow indicates the 1 bp inserted nucleotide in the insertion series. The asterisk indicates the case where a bulge structure different from the wild type is expected. [Figure 17b]FIG. 17 shows a comparison of deletion or insertion probes with 1 bp indel mutants. The expected bulge structure shows that the deletion probe has a simpler and more distinguishable bulge than the insertion probe, even though the mutation position is shifted by several bp (FIG. 17). Therefore, rather than using a 5 bp insertion probe, it is preferable to use a 5 bp deletion probe so that the bulge size is different from the WT even if the 1 bp indel position is several bp away. This is because it is known that the exact indel position induced by a single CRISPR experiment can vary within a range of several bp (Nishida et al., Science 353, (2016)). The expected bulge structure in the wild type and the 1 bp indel mutant with a 5 bp position shift mutation (-2 to +3) is shown. The deletion probe generates a distinguishable and simple bulge structure from all the insertion type (a) and deletion type (b) mutants. On the other hand, for the insertion probe, only the "+1" and "+2" simple bulge structures are obtained in the deletion series (a), and only the "+1" simple bulge structure is obtained in the insertion series (b). The upper strand in the heteroduplex diagram is derived from the sample DNA. The lower strand in the heteroduplex diagram is derived from the probe DNA. The arrow indicates the +1 position. The grey line indicates the null nucleotide. The filled arrow indicates the 5 bp inserted nucleotide in the insertion probe. The unfilled arrow indicates the 1 bp inserted nucleotide in the insertion series. The asterisk indicates the case where a bulge structure different from the wild type is expected. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0006] Summary of the Invention A first aspect of the invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis, comprising: The first nucleic acid sequence S1 is - a first 5' consensus sequence tract C1, and - optionally a first variable sequence tract V1 of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides immediately adjacent in the 3' direction to C1; and - a first 3' consensus sequence tract C2 located 3' to C1; Including, The second nucleic acid sequence S2 is - a second 5' consensus sequence tract C1', and - optionally, a second variable sequence tract V2 of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides immediately adjacent in the 3' direction to C1'; and - a second 3' consensus sequence tract C2' located 3' to C1'; and - said first 5' consensus sequence tract C1 is identical to said second 5' consensus sequence tract C1', or C1' is 1 to 9 nucleotides shorter than C1 at the 3' end, and C1' is identical to C1 from the 5' end of C1 / C1'; and - said first 3' consensus sequence tract C2 is identical to said second 3' consensus sequence tract C2', or C2' is 1 to 9 nucleotides shorter at the 5' end than the first 3' consensus sequence tract C2, and C2' is identical to C2 from the 3' end of C2 / C2'; and with the proviso that S1 and S2 differ from each other in length by 1, 2, 3, 4, 5, 6, 7, 8 or 9 nucleotides with respect to their sequence tracts C1-V1-C2 and C1'-V2-C2', The method includes: contacting said first nucleic acid sequence and said second nucleic acid sequence with a probe sequence P, wherein said probe sequence consists, in a 5' to 3' direction, of a sequence RC2 that is the reverse complement of said 3' consensus sequence tract C2, and a sequence RC1 that is the reverse complement of said 5' consensus sequence tract C1; thereby forming a first probe hybrid and a second probe hybrid under conditions that allow hybridization of said probe sequence to said first and second nucleic acid sequences; and Then, subjecting the first probe hybrid and the second probe hybrid to electrophoresis and detecting the electrophoretic mobility of the first probe hybrid and the second probe hybrid; Includes.
[0007] The method is aimed at detecting small mutations between two nucleic acid sequences. For example, the method can be applied after editing a nucleic acid sequence using a CRISPR / Cas system that can induce non-homologous end joining in a target nucleic acid sequence, thereby generating a single base pair (bp) insertion or deletion compared to a reference sequence.
[0008] In a typical approach, the sequence of the reference sequence and the edited sequence around the 1 bp mutation are amplified by standard PCR techniques to provide the first nucleic acid sequence S1 (e.g., the sense strand of the PCR product of the reference sequence) and the nucleic acid sequence S2 (e.g., the sense strand of the PCR product of the edited sequence having the 1 bp mutation compared to the reference sequence) (Figure 2).
[0009] These PCR products are then denatured and incubated with a probe sequence P. This probe sequence is annealed to sequence S1 at two regions called the consensus sequence tracts, i.e., the probe sequence is antisense (reverse complementary) to the consensus sequence tracts of S1 and S2. The 5' consensus sequence tract and the 3' consensus sequence tract are flanked by variable regions called variable sequence tracts, e.g., a 5 nucleotide (nt) sequence tract around a mutation site. Upon hybridization of nucleic acid sequence S1 with the probe sequence, a 5 nt variable sequence tract will protrude.
[0010] The same is true for sequence S2. Here too, the probe sequence will hybridize to the 5' and 3' consensus sequence tracts. Compared to sequence S1, the variable sequence tract is 1 base longer (in the case of a 1 bp insertion) or 1 base shorter (in the case of a 1 bp deletion). Thus, there will be a 6 nt (insertion) or 4 nt (deletion) overhang.
[0011] When the S1-P-hybrid (first probe hybrid) and the S2-P-hybrid (second probe hybrid) are subjected to electrophoresis such as polyacrylamide gel electrophoresis or a high-resolution electrophoresis device (e.g., MultiNA or QIAxcel), the electrophoretic mobility of the first probe hybrid differs from that of the second probe hybrid due to the different sizes of the bulges (protrusions) formed by the first and second variable sequence tracts.
[0012] It is also possible for the probe sequence to overhang. For example, the reference sequence S1 may include a first 5' common sequence tract, a first 3' common sequence tract, and a variable sequence tract of, for example, 5 nt length. The edited nucleic acid sequence S2 may include a deletion of several base pairs (for example, 8 bp) compared to the reference sequence S1.
[0013] Thus, the 5′ consensus sequence tract C1′ of edited sequence S2 is 3 nt shorter than the consensus sequence tract C1 of reference sequence S1 (FIG. 3).
[0014] When hybridized with probe sequence P, which consists of a sequence that is reverse complementary to C1 and C2, the variable sequence tract V1 will form a 5 nt bulge. When the probe hybridizes to edited sequence S2, the probe will form a 3 nt bulge. Again, when subjected to electrophoresis, the electrophoretic mobility of the S1-P-hybrid is different from that of the S2-P-hybrid.
[0015] Detailed Description of the Invention Terms and Definitions Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., cell culture, molecular genetics, nucleic acid chemistry, hybridization techniques, and biochemistry). Standard techniques are used for molecular, genetic, biochemical techniques (see generally, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, and Ausubel et al., Short Protocols in Molecular Biology (1999) 4th ed., John Wiley & Sons, Inc.) and chemical techniques.
[0016] The term "capable of forming a hybrid or hybridizing sequence" in the context of this specification relates to a sequence that is capable of selectively binding to its target sequence under conditions that can typically exist in gels used for the electrophoretic separation of polynucleotides.
[0017] The term "nucleotide" in the context of this specification refers to a building block of a nucleic acid or a nucleic acid analog, which oligomer is capable of forming selective hybrids with an RNA or DNA oligomer based on base pairing. The term "nucleotide" in this context includes the building blocks of classical ribonucleotides adenosine, guanosine, uridine (and ribosylthymine), cytidine, and the classical deoxyribonucleotides deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. It further includes analogs of nucleic acids such as phosphothioates, 2'O-methylphosphothioates, "peptide nucleic acid" (PNA; N-(2-aminoethyl)-glycine units linked by peptide bonds with the nucleic acid base attached to the alpha carbon of glycine) or "locked nucleic acid" (LNA; 2'O,4'C methylene bridged RNA building block). As used herein, when a "hybridizing sequence" is referred to, such a hybridizing sequence may be composed of any of the above nucleotides, or a mixture thereof.
[0018] The term "reverse complementary" in the context of this specification refers to a nucleotide sequence having a sequence displayed 5' to 3' that is substantially complementary to and capable of hybridizing to a reference sequence. For example, if the reference sequence is 5'AATGC3', then its reverse complementary sequence is 5'GCATT3'. "Complementary" may be used synonymously with "reverse complementary".
[0019] In the context of this specification, the term "hybridizing sequence" encompasses polynucleotide sequences that comprise or consist essentially of RNA (ribonucleotides), DNA (deoxyribonucleotides), phosphothioate deoxyribonucleotides, 2'-O-methyl modified phosphothioate ribonucleotides, LNA and / or PNA nucleotide analogs.
[0020] Detailed Description A first aspect of the invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis, comprising: wherein the electrophoretic mobility of the first nucleic acid sequence is indistinguishable from the electrophoretic mobility of the second nucleic acid sequence; and The first nucleic acid sequence S1 is - a first 5' consensus sequence tract C1, and - a first variable sequence tract V1, which may be 1 to 10 nucleotides in length, immediately adjacent in the 3' direction to a first 5' consensus sequence tract C1 and immediately adjacent in the 5' direction to a first 3' consensus sequence tract C2; and - a first 3' consensus sequence tract C2 located in the 3' direction of C1 and immediately adjacent in the 3' direction to the first variable sequence tract V1, if V1 is present; Including, The second nucleic acid sequence S2 is - a second 5' consensus sequence tract C1', and - optionally a second variable sequence tract V2, which may be 1 to 10 nucleotides in length, immediately adjacent in the 3' direction to a second 5' consensus sequence tract C1' and immediately adjacent in the 5' direction to a second 3' consensus sequence tract C2'; and - a second 3' consensus sequence tract C2' located in the 3' direction of C1' and, if V2 is present, immediately adjacent in the 3' direction to the second variable sequence tract V2; and - said first 5' consensus sequence tract C1 is identical to said second 5' consensus sequence tract C1', or the second 5' consensus sequence tract C1' is 1 to 9 nucleotides shorter at the 3' end than the first 5' consensus sequence tract C1, and the second 5' consensus sequence tract C1' is identical to the first 5' consensus sequence tract C1 from the 5' end of C1 / C1' to positions -9 to -1 upstream of the 3' end (5' direction); and - said first 3' consensus sequence tract C2 is identical to said second 3' consensus sequence tract C2', or the second 3' consensus sequence tract C2' is 1 to 9 nucleotides shorter at the 5' end than the first 3' consensus sequence tract C2, and the second 3' consensus sequence tract C2' is identical to the first 3' consensus sequence tract C2 from the +9 to +1 position downstream (3' direction) of the 5' end to the 5' end; and - at least one of the first and second nucleic acid sequences comprises a first or second variable sequence tract if both the first 5' consensus sequence tract and the first 3' consensus sequence tract are identical to the second 5' consensus sequence tract and the second 3' consensus sequence tract; and - if the variable sequence tract is present and C1 is identical to C1' and C2 is identical to C2', then the first variable sequence tract differs from the second variable sequence tract at at least one position; and - in certain embodiments, said first variable sequence tract and / or said second variable sequence tract is at least 2 nucleotides in length; with the proviso that S1 and S2 differ from each other in length by ≦10 nucleotides with respect to their sequence tracts C1-V1-C2 and C1'-V2-C2'; The method comprises: contacting said first and second nucleic acid sequences with a probe sequence P, wherein said probe sequence consists, in a 5' to 3' direction, of a sequence RC2 that is reverse complementary to said 3' common sequence tract C2, and a sequence RC1 that is reverse complementary to said 5' common sequence tract C1, thereby forming a first probe hybrid and a second probe hybrid under conditions allowing hybridization of said probe sequences to said first and second nucleic acid sequences, thereafter subjecting said first and second probe hybrids to electrophoresis and detecting the electrophoretic mobilities of said first and second probe hybrids; Includes.
[0021] According to one alternative embodiment of this aspect of the invention, the method for distinguishing a first nucleic acid sequence S1 from a second nucleic acid sequence S2 by electrophoresis uses the sequence as follows: The first nucleic acid sequence S1 is - a first 5' consensus sequence tract C1, and - a first variable sequence tract V1 of 1 to 10 nucleotides immediately adjacent in the 3' direction to C1; and - a first 3' consensus sequence tract C2 located 3' to C1; Including, The second nucleic acid sequence S2 is - a second 5' consensus sequence tract C1', and - a second 3' consensus sequence tract C2' located 3' to C1' and - said first 5' consensus sequence tract C1 is identical to said second 5' consensus sequence tract C1'; and - said first 3' consensus sequence tract C2 is identical to said second 3' consensus sequence tract C2'; and - S1 and S2 differ from each other by ≦10 nucleotides in length with respect to their sequence tracts C1-V1-C2 and C1′-C2′. The method includes contacting a first nucleic acid sequence and a second nucleic acid sequence with a probe sequence P, where the probe sequence consists, in a 5' to 3' direction, of a sequence RC2 that is reverse complementary to the 3' common sequence tract C2, and a sequence RC1 that is reverse complementary to the 5' common sequence tract C1, thereby forming a first probe hybrid and a second probe hybrid under conditions that allow hybridization of the probe sequences to the first and second nucleic acid sequences, and then subjecting the first and second probe hybrids to electrophoresis and detecting the electrophoretic mobility of the first and second probe hybrids.
[0022] According to another alternative embodiment of this aspect of the invention, a method for distinguishing a first nucleic acid sequence S1 from a second nucleic acid sequence S2 by electrophoresis uses the sequence as follows: The first nucleic acid sequence S1 is - a first 5' consensus sequence tract C1, and - a first variable sequence tract V1 of 1 to 10 nucleotides immediately adjacent in the 3' direction to C1; and - a first 3' consensus sequence tract C2 located 3' to C1; Including, The second nucleic acid sequence S2 is - a second 5' consensus sequence tract C1', and - a second variable sequence tract V2 of 1 to 10 nucleotides immediately adjacent in the 3' direction to C1'; and - a second 3' consensus sequence tract C2' located 3' to C1'; and - said first 5' consensus sequence tract C1 is identical to said second 5' consensus sequence tract C1'; and - said first 3' consensus sequence tract C2 is identical to said second 3' consensus sequence tract C2'; and - S1 and S2 differ from each other with respect to their sequence tracts C1-V1-C2 and C1'-C2' by a length of ≦10 nucleotides. The method comprises: As described above, the method comprises contacting said first and second nucleic acid sequences with a probe sequence P as defined above, under conditions allowing hybridization of said probe sequences to said first and second nucleic acid sequences, thereafter subjecting the first and second probe hybrids to electrophoresis and detecting the electrophoretic mobility of the first and second probe hybrids.
[0023] In yet a further alternative embodiment of this aspect of the invention, C1 and C1' or C2 and C2' of a pair of constant sequence tracts may differ at their "distal ends", i.e. at the ends opposite the end where C1 is closest to C2 and C1' is closest to C2'.
[0024] In such alternative embodiments, C1' is 1 to 9 nucleotides shorter at the 3' end than C1 and C1' is identical to C1 from the 5' end of C1 / C1'. Alternatively, C2' is 1 to 9 nucleotides shorter at the 5' end than the first 3' consensus sequence tract C2 and C2' is identical to C2 from the 3' end of C2 / C2'.
[0025] As described above, the sequences S1 and S2 can be obtained, for example, by performing standard PCR on the reference sequence and the edited sequence. Thus, the first nucleic acid sequence and the second nucleic acid sequence have a common length for the PCR product.
[0026] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 40 nucleotides and 3500 nucleotides.
[0027] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 60 nucleotides and 3500 nucleotides.
[0028] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 80 nucleotides and 3500 nucleotides.
[0029] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 100 nucleotides and 3500 nucleotides.
[0030] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 150 and 350 nucleotides, in particular between 150 and 250 nucleotides.
[0031] In a particular embodiment, the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 180 and 220 nucleotides.
[0032] The first nucleic acid sequence S1 and the second nucleic acid sequence S2 comprise a common sequence tract. When incubated with a probe sequence, the probe sequence hybridizes to the common sequence tract.
[0033] According to the present invention, the first nucleic acid sequence S1 and the second nucleic acid sequence S2 can start at their 5' ends with a common sequence tract and end at their 3' ends with a common sequence tract. In this way, the probe hybridizes over the entire length of S1 and S2, except for the bulge region around the mutation site. Such an embodiment is also called "pre-PRIMA".
[0034] Alternatively, the first nucleic acid sequence S1 and the second nucleic acid sequence S2 may not start at their 5' and 3' ends in a common sequence tract. In this case, the probe does not hybridize to the sequence immediately adjacent in the 5' direction (upstream) to the 5' common sequence tract, and does not hybridize to the sequence immediately adjacent in the 3' direction (downstream) to the 3' common sequence tract. Such an embodiment is also called "PRIMA".
[0035] In certain embodiments, the first nucleic acid sequence S1 comprises at least 5 nucleotides immediately adjacent in the 5' direction to a first 5' common sequence tract C1 and at least 5 nucleotides immediately adjacent in the 3' direction to a first 3' common sequence tract C2, and the second nucleic acid sequence S2 comprises at least 5 nucleotides immediately adjacent in the 5' direction to a second 5' common sequence tract C1' and at least 5 nucleotides immediately adjacent in the 3' direction to a second 3' common sequence tract C2'.
[0036] In certain embodiments, the first nucleic acid sequence S1 comprises at least 35 nucleotides immediately adjacent in the 5' direction to a first 5' common sequence tract C1 and at least 35 nucleotides immediately adjacent in the 3' direction to a first 3' common sequence tract C2, and the second nucleic acid sequence S2 comprises at least 35 nucleotides immediately adjacent in the 5' direction to a second 5' common sequence tract C1' and at least 35 nucleotides immediately adjacent in the 3' direction to a second 3' common sequence tract C2'.
[0037] In a particular embodiment, the first nucleic acid sequence S1 comprises at least 47 nucleotides, particularly 50 nucleotides, immediately adjacent in the 5' direction to the first 5' common sequence tract C1 and at least 47 nucleotides, particularly 50 nucleotides, immediately adjacent in the 3' direction to the first 3' common sequence tract C2, and the second nucleic acid sequence S2 comprises at least 47 nucleotides, particularly 50 nucleotides, immediately adjacent in the 5' direction to the second 5' common sequence tract C1' and at least 47 nucleotides, particularly 50 nucleotides, immediately adjacent in the 3' direction to the second 3' common sequence tract C2'.
[0038] The probe sequence can be obtained by PCR or oligonucleotide synthesis. When carrying out the method for S1 and S2 sequences that do not start and end in a common sequence tract ("PRIMA"), the probe sequence is usually obtained by oligonucleotide synthesis. The probe is reverse complementary to the first 5' common sequence tract C1 and the first 3' common sequence tract C2.
[0039] In certain embodiments, the total length of the probe is between 18 and 80 nucleotides.
[0040] In certain embodiments, the total combined length of the first 5' consensus sequence tract C1 and the first 3' consensus sequence tract C2 is between 18 and 80 nucleotides.
[0041] In certain embodiments, the total combined length of the second 5' consensus sequence tract C1 and the second 3' consensus sequence tract C2 is between 18 and 80 nucleotides.
[0042] When carrying out the method on S1 and S2 sequences beginning and ending in a consensus sequence tract ("pre-PRIMA"), a probe sequence is usually obtained by PCR, which is reverse complementary to the first 5' consensus sequence tract C1 and the first 3' consensus sequence tract C2.
[0043] In a particular embodiment, the total length of the probe is between 18 and 3500 nucleotides, in particular between 40 and 80 nucleotides.
[0044] In certain embodiments, the total combined length of the first 5' consensus sequence tract C1 and the first 3' consensus sequence tract C2 is between 150 and 300 nucleotides.
[0045] In certain embodiments, the total combined length of the second 5' consensus sequence tract C1 and the second 3' consensus sequence tract C2 is between 200 and 250 nucleotides.
[0046] To allow easy discrimination of differences in electrophoretic mobility, the probe must be designed to form a stable bulge region, i.e., the probe sequence must stably hybridize to 5' and 3' consensus sequence tracts upstream and downstream of the mutation site.
[0047] In a particular embodiment, the ratio between the length of the first 5' consensus sequence tract C1 and the length of the first 3' consensus sequence tract C2 is between 1:7 and 7:1, and the minimum length of the first 5' consensus sequence tract C1 and the minimum length of the first 3' consensus sequence tract C2 is 5 nucleotides, in particular 10 nucleotides, more in particular 20 nucleotides.
[0048] In a particular embodiment, the ratio between the length of the first 5' consensus sequence tract C1 and the length of the first 3' consensus sequence tract C2 is between 3:5 and 5:3, and the minimum length of the first 5' consensus sequence tract C1 and the minimum length of the first 3' consensus sequence tract C2 is 5 nucleotides, in particular 10 nucleotides, more in particular 20 nucleotides.
[0049] In a particular embodiment, the ratio between the length of the first 5' consensus sequence tract C1 and the length of the first 3' consensus sequence tract C2 is 1:1, and the minimum length of the first 5' consensus sequence tract C1 and the minimum length of the first 3' consensus sequence tract C2 is 5 nucleotides, in particular 10 nucleotides, more in particular 20 nucleotides.
[0050] In particular, a bulge region between 4 and 6 nucleotides is suitable for detecting a 1 bp deletion or insertion in one of the sequences S1 or S2 relative to the other sequence S2 or S1, respectively. For example, a bulge having a length of 5 nucleotides (e.g., in a hybrid of a reference sequence and a probe) can be distinguished from a bulge having a length of 4 nucleotides (e.g., in a hybrid of an edited sequence with a 1 bp deletion and a probe) or from a bulge having a length of 6 nucleotides (e.g., in a hybrid of an edited sequence with a 1 bp insertion and a probe). The bulge can be formed by the variable sequence tracts of S1 and S2.
[0051] In certain embodiments, the first variable sequence tract V1 and the second variable sequence tract V2, independently of each other, have a length between 4 and 10 nucleotides.
[0052] In certain embodiments, the first variable sequence tract V1 and the second variable sequence tract V2, independently of each other, have a length between 4 and 6 nucleotides.
[0053] Sequences S1 and S2 may differ in length, e.g., S2 exhibits a deletion or insertion compared to S1. Alternatively, or in addition, S1 and S2 may differ in base sequence, e.g., ATG CT TC is ATG T.C. TC is different. Also, for example, S1 is S2, and ATC is G TTC and ATG C Compositional differences may also occur, such as differences in substitutions such as TTC. To detect such differences, probes can be designed such that the mutation site is within a variable sequence tract that is flanked by consensus sequence tracts.
[0054] In certain embodiments, the first variable sequence tract V1 differs from the second variable sequence tract V2 in length (deletion / insertion) and / or the base sequence and / or composition of the first variable sequence tract V1 differs from the base sequence and / or composition of the second variable sequence tract V2 at at least one position (substitution).
[0055] In certain embodiments, the first variable sequence tract V1 differs in length from the second variable sequence tract V2 (deletion / insertion) and / or the composition of the first variable sequence tract V1 differs from the composition of the second variable sequence tract V2 at at least one position (substitution).
[0056] In certain embodiments, the first variable sequence tract V1 differs in length (deletion / insertion) from the second variable sequence tract V2.
[0057] In certain embodiments, the length of the first variable sequence tract V1 differs from the length of the second variable sequence tract V2 by ≦10 nucleotides.
[0058] In certain embodiments, the length of the first variable sequence tract V1 differs from the length of the second variable sequence tract V2 by ≦2 nucleotides.
[0059] In certain embodiments, the length of the first variable sequence tract V1 differs from the length of the second variable sequence tract V2 by one nucleotide.
[0060] In a particular embodiment, the composition of the first variable sequence tract V1 differs from the composition of the second variable sequence tract V2 at two positions, in particular at one position.
[0061] As mentioned above, the method can be carried out on sequences obtained by PCR, in which case the first and second nucleic acid sequences S1, S2 and / or the probe sequence are double-stranded.
[0062] In certain embodiments, the first nucleic acid sequence S1 hybridizes to its reverse complement and / or the second nucleic acid sequence S2 hybridizes to its reverse complement.
[0063] In certain embodiments, the probe sequence P hybridizes to its reverse complement.
[0064] In certain embodiments, the first and second probe hybrids are obtained by applying a temperature above the melting temperatures of the first and second nucleic acid sequences, followed by a temperature below the melting temperature of the probe sequence.
[0065] An alternative embodiment of the present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis, comprising: wherein the electrophoretic mobility of the first nucleic acid sequence is indistinguishable from the electrophoretic mobility of the second nucleic acid sequence; And (see Figure 16) The first nucleic acid sequence comprises: - a first variable sequence tract, - a first 5' consensus sequence tract C1 immediately adjacent in the 5' direction to said first variable sequence tract, and - a first 3' consensus sequence tract C2 immediately adjacent in the 3' direction to said first variable sequence tract; Including, The second nucleic acid sequence comprises: optionally a second variable sequence tract, - a second 5' consensus sequence tract C1', which is identical to the first 5' consensus sequence tract and which is immediately adjacent in the 5' direction to the second variable sequence tract; and - a second 3' consensus sequence tract C2' which is identical to the first 3' consensus sequence tract and which is immediately adjacent in the 3' direction to the second variable sequence tract; Including, and - said first variable sequence tract differs from said second variable sequence tract at at least one position; and - the first variable sequence tract comprises a first sequence tract H and / or a first sequence tract A and optionally a first sequence tract U, wherein the first sequence tract H is identical to a second sequence tract H' of the second variable sequence tract, the first sequence tract A is reverse complementary to a sequence tract RA of the probe sequence, and the sequence tract U is unique to the first sequence; and - if the first variable sequence tract comprises the sequence tract H, then the second variable sequence tract comprises the sequence tract H'; and - the second variable sequence tract may comprise a second sequence tract U' that is unique to the second sequence, The method comprises: contacting said first nucleic acid sequence and said second nucleic acid sequence with a probe sequence, wherein said probe sequence comprises, in a 5' to 3' direction, a sequence RC2 that is reverse complementary to said 3' common sequence tract C2, and a sequence RC1 that is reverse complementary to said 5' common sequence tract C1, and optionally a variable sequence tract RV that includes a sequence tract RA that is reverse complementary to sequence tract A and / or a sequence tract P that does not hybridize to either the first variable sequence tract or the second variable sequence tract; thereby forming a first probe hybrid and a second probe hybrid under conditions that allow hybridization of said first and second nucleic acid sequences with said probe sequence; and thereafter, subjecting the first and second probe hybrids to electrophoresis and detecting the electrophoretic mobilities of the first and second probe hybrids; Includes.
[0066] array The diagram shows the following sequence: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] EXAMPLES
[0067] Example 1: Heteroduplex mobility assay (HMA) patterns and resolution We tested the banding pattern of conventional HMA using Shimadzu's microchip electrophoresis system, MultiNA. The wild-type sequence and mutant sequences with different lengths of deletion, i.e., 0 bp (wild-type) to 7 bp deletion sequences, were amplified by PCR separately. The wild-type PCR product was then mixed with the mutant sequence PCR product, respectively. These mixtures were denatured and reannealed to result in heteroduplex complexes. If the gap is long enough, the mismatched DNA sequence will have a bulge caused by looping out of the bases, causing a mobility shift (Bhattacharyya and Lilley, 1989 NAR). Similar to the results shown previously, we could not detect any 1 bp difference in the heteroduplex peaks (Bhattacharyya and Lilley, 1989 NAR). The heteroduplex peak with a 2 bp gap was also not clear (Ota et al., 2013 Genes Cells, Ansai et al., 2014 Dev Growth Differ).
[0068] Example 2: HMA with 5 bp deletion probe (prePRIMA) The inventors carried out their research with the aim of detecting differences in length of 1 bp. Using five genes from either Arabidopsis (A. thaliana), bacteria, or humans, the inventors tested whether it was possible to distinguish between 4 bp (= 1 bp deletion), 5 bp (= wild type), and 6 bp (= 1 bp insertion). Indeed, the inventors clearly distinguished between 1 bp insertions and deletions in all cases (Figure 4). The inventors applied this technique to prePRIMA ( p recursive method of Pr obe- I Induced H MA ) (a pioneering method for probe-guided HMA).
[0069] We further investigated the effect of the size and / or the different sequences of the PCR fragments (Figures 5 and 6). Fragments with a size of about 200 bp worked effectively to detect different heteroduplex peaks among the 3-7 bp gap fragments (Figure 7). Shorter fragments (i.e., 130 bp for RDP1 and 153 bp for DML1 in Figures 5b and 6a) were not sufficient to obtain clear differences. Heteroduplex peaks derived from 300 bp fragments can overlap with the upper marker in our system and cannot be analyzed by the MultiNA chip500 (Figures 5c, 6c).
[0070] Furthermore, we aimed to optimize the design of the probe: the probe performed better with a gap region overlapping the mutation site in the middle of the PCR fragment than at the end of the PCR fragment (Figure 8).
[0071] Example 3: PRIMA with short single-stranded DNA (sssDNA) probes Producing a probe with a 5 bp deletion in the middle of a 200 bp PCR fragment is time consuming because it requires two steps of PCR or cloning (Braman 2004, Springer protocols / Methods in Mol Biol 634). Otherwise, it is possible to order longer oligos, but the cost is relatively high.
[0072] To overcome these obstacles, we investigated whether single-stranded DNA (ssDNA) was sufficient to generate heteroduplexes with looped-out bases. The results are shown in Figure 8c. ssDNA (80mer) was sufficient to discriminate sequences that differed by 1 bp. It was also possible to shorten this ssDNA probe to reduce the cost of oligonucleotide synthesis. We found that short ssDNA (sssDNA), such as 40mer, was sufficient (Figure 8c). From these findings, we proposed the method as a PRIMA ( Pr obe- I Induced Heteroduplex M obility A This was named the probe-induced heteroduplex mobility assay (probe-induced heteroduplex mobility assay). It is also important to note that the sssDNA is more preferably set near the center of the DNA fragment (FIG. 8).
[0073] Example 4: Screening with PRIMA We tested PRIMA using mutant sequences of 10 deletions to 10 insertions of RDP1 (Figure 9). We obtained heteroduplex peaks of different sizes of deletion sequences relative to insertion sequences (Figure 9). These results suggest that PRIMA can function in screening mutants. This could be of great help to a wide range of biological researchers in reducing time and costs.
[0074] Example 5: Genotyping with PRIMA Although traditional HMA has been used for genotyping (Ansai et al., 2014 Dev Growth Differ), as shown above, the resolution of HMA is low (Figure 1). This low resolution makes it impossible to distinguish heterozygous genotypes with a difference of 1 bp. Even when a difference of several bp can be detected from the mobility shift of heteroduplexes, the small difference (a few bp) is often indistinguishable between two homozygous genotypes (i.e., wild type and mutant type). The researchers performed another set of samples with HMA to distinguish these homozygous wild type and mutant types (Figure 10a).
[0075] To save time, two runs can be performed simultaneously, but the researchers must analyze twice the number of samples.
[0076] On the other hand, prePRIMA and PRIMA can distinguish genotypes in a single run (Figures 11 and 10). When the 5 bp deletion sequence was used as a probe, it was observed that the heteroduplex peaks derived from wild-type homozygotes or mutant homozygotes showed different mobility shifts. Heterozygote samples showed both peaks (Figures 10c and 10d). In summary, prePRIMA and PRIMA can save costs, efforts, and / or time in genotyping compared to HMA. PRIMA is recommended as the method of choice for genotyping because it does not require the synthesis of long probes compared to prePRIMA.
[0077] Example 6: PRIMA is applicable to many sequences We tested the applicability of PRIMA to several plant, bacterial, and human sequences, and were successful in detecting heteroduplex peaks of different sizes for different genotypes and materials using PRIMA (and prePRIMA) (Figure 13).
[0078] When we encountered cases where the peak patterns from the short single-stranded DNA (sssDNA) probe (forward probe) were not very clearly distinguishable, we tried another strand of sssDNA (reverse probe). We tested the same PCR fragment and the complementary sequence as a probe in the same probe region. We detected differences in the mobility of the heteroduplex peaks using either the forward or reverse probe (Figure 13). This result is comparable to the HMA case of Bhattacharyya and Lilley, 1989 NAR. Different peaks were detected by the complementary probe. Usually, at least one of these two probes showed clear differences depending on the genotype (Figure 13). If both strands did not work, a small shift in the position of the probe was performed.
[0079] Example 7: PRIMA can distinguish between base types (A, T, G, C) Recent developments in the CRISPR system have enabled "base editing" using a nuclease-inactivated version of SpCas9 (Kumor et al., Nature 2016; Nishida et al., Science 2016; Nishimasu et al., 2018). To test whether PRIMA can be used to distinguish between types of bases, we performed PRIMA (Figure 13). We were able to distinguish between A and T at the same position (Figure 13b). This result further expands the possibility that PRIMA can be applied to single nucleotide polymorphism (SNP) typing in addition to detecting indels. SNP typing is also useful for chemically mutated genotypes (such as EMS mutants in plants). Homologs can be distinguished by PRIMA.
[0080] method PRIMA procedure using the MultiNA DNA-500 kit (Figure 15) 1. Set PCR conditions based on the target site for genome editing. Design primers that satisfy the following conditions: Forward primer position: (presumed) approximately 100 bp upstream of the mutation position. Reverse primer position: approximately 100 bp downstream of the (presumed) mutation position. It is recommended that these primers be designed so that the product size is 180-220 bp. 2. Design a probe that contains a 5 bp deletion around the (putative) mutation site. PRIMA works with short single stranded DNA (sssDNA). We confirmed that a 40mer sssDNA is long enough to induce a structural change after the reannealing process in step 4. We recommend that the probe position 5 bp deletion starts at -6 to -2 of the PAM sequence (see Figure 15). 3.PCR The primers from step 1 are used to prepare a PCR fragment using standard PCR procedures. 4. Prepare a mixture of PCR products and probes and reanneal. Mix 9 μl of PCR product with 1 μl of 10 μM probe prepared in step 2. The denaturation and reannealing reaction is then carried out as follows: 95° C. for 5 min, cooling to 25° C. at 0.1° C. per second. 5. Detect the heteroduplex peak. The heteroduplex peak can be detected by Shimadzu's MultiNA microchip electrophoresis system. This detection step can be achieved by polyacrylamide gel electrophoresis (Ota et al., 2013 Genes Cells; Ansai et al., 2014 Dev Growth Differ; Delwart et al., 1993 Science) or other high-resolution electrophoresis devices (i.e., QIAxcel from Qiagen).
Claims
1. 1. A method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis, comprising: The first nucleic acid sequence S1 comprises: a first 5' consensus sequence tract C1, and - a first variable sequence tract V1 of 1 to 10 nucleotides immediately adjacent in the 3' direction to C1; and - a first 3' consensus sequence tract C2 located 3' to C1; Including, The second nucleic acid sequence S2 comprises: a second 5' consensus sequence tract C1', and - optionally a second variable sequence tract V2 of 1 to 10 nucleotides immediately adjacent in the 3' direction to C1'; and - a second 3' consensus sequence tract C2' located 3' to C1'; and - said first 5' consensus sequence tract C1 is identical to said second 5' consensus sequence tract C1', or C1' is 1 to 9 nucleotides shorter than C1 at the 3' end, and C1' is identical to C1 from the 5' end of C1 / C1'; and said first 3' consensus sequence tract C2 is identical to said second 3' consensus sequence tract C2', or C2' is 1 to 9 nucleotides shorter at the 5' end than the first 3' consensus sequence tract C2, and C2' is identical to C2 from the 3' end of C2 / C2'; and with the proviso that S1 and S2 differ from each other in length by ≦10 nucleotides with respect to their sequence tracts C1-V1-C2 and C1′-V2-C2′, The method comprises: contacting said first nucleic acid sequence and said second nucleic acid sequence with a probe sequence P, wherein said probe sequence consists, in a 5' to 3' direction, of a sequence RC2 which is reverse complementary to said 3' consensus sequence tract C2, and a sequence RC1 which is reverse complementary to said 5' consensus sequence tract C1; forming a first probe hybrid and a second probe hybrid under conditions that allow hybridization of said probe sequence with said first nucleic acid sequence and said second nucleic acid sequence; and thereafter, subjecting the first probe hybrid and the second probe hybrid to electrophoresis, and detecting the electrophoretic mobility of the first probe hybrid and the second probe hybrid; The method comprising:
2. 2. The method of claim 1, wherein the length of the first nucleic acid sequence S1 and the length of the second nucleic acid sequence S2 are between 40 nucleotides and 3500 nucleotides.
3. 3. The method of claim 1 or 2, wherein the first nucleic acid sequence S1 comprises at least 5 nucleotides immediately adjacent in the 5' direction to the first 5' common sequence tract C1 and at least 5 nucleotides immediately adjacent in the 3' direction to the first 3' common sequence tract C2, and the second nucleic acid sequence S2 comprises at least 5 nucleotides immediately adjacent in the 5' direction to the second 5' common sequence tract C1' and at least 5 nucleotides immediately adjacent in the 3' direction to the second 3' common sequence tract C2'.
4. The method according to any one of claims 1 to 3, wherein the total combined length of the first 5' consensus sequence tract C1 and the first 3' consensus sequence tract C2 is between 18 nucleotides and 3500 nucleotides.
5. 5. The method of claim 1, wherein the ratio of the length of the first 5' consensus sequence tract C1 to the length of the first 3' consensus sequence tract C2 is between 1:7 and 7:1, and the minimum length of the first 5' consensus sequence tract C1 and the first 3' consensus sequence tract C2 is 5 nucleotides.
6. 6. The method of any one of claims 1 to 5, wherein the first variable sequence tract V1 and the second variable sequence tract V2 are, independently of each other, between 4 and 10 nucleotides in length.
7. The method according to any one of claims 1 to 6, wherein the first variable sequence tract V1 differs in length from the second variable sequence tract V2, and / or the base sequence and / or composition of the first variable sequence tract V1 differs from the base sequence and / or composition of the second variable sequence tract V2 at at least one position.
8. 8. The method of claim 1, wherein the length of the first variable sequence tract V1 differs from the length of the second variable sequence tract V2 by ≦10 nucleotides.
9. The method of any one of claims 1 to 8, wherein the composition of the first variable sequence tract V1 differs from the composition of the second variable sequence tract V2 at two positions.
10. The method according to any one of claims 1 to 9, wherein the first nucleic acid sequence S1 hybridizes to its reverse complementary sequence and / or the second nucleic acid sequence S2 hybridizes to its reverse complementary sequence.
11. The method according to any one of claims 1 to 10, wherein the probe sequence P hybridizes to its reverse complement.
12. 12. The method according to any one of claims 1 to 11, wherein the first and second probe hybrids are obtained by applying a temperature above the melting points of the first and second nucleic acid sequences, followed by applying a temperature below the melting point of the probe sequence.
Citation Information
Patent Citations
Simple method of detecting methylcytosine
WO2006132022A1
